Admission B-Type Natriuretic Peptide Levels and In-Hospital Mortality in Acute Decompensated Heart Failure Fonarow GC et al. J Am Coll Cardiol 2007; 49(19):1943-1950.

Slides:



Advertisements
Similar presentations
Literature Search Strategy Used for the MEDLINE Database Gami AS, et al. J Am Coll Cardiol 2007;49:
Advertisements

© 2010, American Heart Association. All rights reserved. Hospital Performance Recognition with the Get with the Guidelines Program and Mortality for Acute.
© 2010, American Heart Association. All rights reserved. A Validated Risk Score for In-hospital Mortality in Patients with Heart Failure from the American.
Associations Between Outpatient Heart Failure Process of Care Measures and Mortality Gregg C. Fonarow, Nancy M. Albert, Anne B. Curtis, Mihai Gheorghiade,
Perioperative Management of Heart Failure Gamal Fouad S Zaki, MD Professor of Anesthesiology Ain Shams University
Trends in the Use of Evidence-Based Treatments for Coronary Artery Disease Among Women and the Elderly Findings From the Get With the Guidelines Quality-
Maria Rosa Costanzo, M.D., F.A.C.C., F.A.H.A. Medical Director, Midwest Heart Specialists-Advocate Medical Group Heart Failure and Pulmonary Arterial Hypertension.
A Risk Score for Predicting Coronary Artery Bypass Surgery in Patients with Non-ST Elevation Acute Coronary Syndromes Sai Sadanandan, MD*; Christopher.
“Influence of age on the management of heart failure: Findings from Get With the Guidelines–Heart Failure (GWTG-HF)” Daniel E. Forman, MD; Christopher.
“ Age-Related Differences in Characteristics, Performance Measures, Treatment Trends, and Outcomes in Patients with Ischemic Stroke ” Gregg C. Fonarow,
“Hospital Performance Recognition with the Get with the Guidelines Program and Mortality for Acute Myocardial Infarction and Heart Failure Paul A Heidenreich,
Fonarow GC, et al. J Am Coll Cardiol. 2007;50:768  777. Characteristics, Treatments, and Outcomes of Patients With Preserved Systolic Function Hospitalized.
CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin.
Heart Failure: From Failure to Success
PEACE BNP: Omland, T. et al. J Am Coll Cardiol 2007; 50:205–14 Copyright ©2007 American College of Cardiology Foundation. Restrictions may apply. Prognostic.
METHODS Setting: Wesley Medical Center (Wichita, Kansas), a 760-bed tertiary care facility and teaching hospital with a 45-bed ICU and a 20-bed CCU. Study.
Current treatment of acute heart failure Department of Cardiology of the University Medical Center Belgrade, Serbia Prof. Petar M. Seferović, MD, PhD,
S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Efficacy and safety of ivabradine in patients with severe chronic systolic.
Acute Heart Failure in Apical Ballooning Syndrome (Takotsubo/Stress Cardiomyopathy) Clinical Correlates and Mayo Clinic Risk Score Malini Madhavan, MBBS;
Treatment and Risk in Heart Failure: Gaps in Evidence or Quality? Pamela N. Peterson, MD MSPH; John S. Rumsfeld, MD PhD; Li Liang PhD; Adrian F. Hernandez,
All Rights Reserved, Duke Medicine 2008 Mechanical Dyssynchrony Defined by Phase Analysis from GSPECT: Does It Predict Mortality? Paul L. Hess, MD; Linda.
Distribution of metabolic syndrome (MS) components by age and gender Zhao D, et al. Am J Cardiol 2007;100:835– 839.
NTproBNP for the Exclusion of Heart Failure Richard Blakey.
Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Relationship Between Operator Volume and Adverse.
WELCOME BNP testing. Aims of this education package Better understanding of what BNP testing is How to appropriately use the test How to request the.
The CHART-2 Study (The Chronic Heart Failure Analysis and Registry in the Tohoku District 2) Source Shiba N, Nochioka K, Miura M, et al. Trend of westernization.
Mahmoud Farhoud, MD 1,2, Paul Ndunda, MD 2,K James Kallail, PhD 2, Hussam Farhoud, MD, FACC 3 1 University of Central Florida College of Medicine, 2 University.
Date of download: 6/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: Utility of B-type natriuretic peptide in the diagnosis.
Date of download: 7/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Scope of Coronary Heart Disease in Patients With.
Brain Natriuretic Peptide is a Prognostic Parameter in Chronic Lung Disease Hanno H. Leuchte, Rainer A. Baumgartner, Michal El Nounou, Michael Vogeser,
From: Contemporary Mortality Risk Prediction for Percutaneous Coronary Intervention: Results From 588,398 Procedures in the National Cardiovascular Data.
From: Contemporary Mortality Risk Prediction for Percutaneous Coronary Intervention: Results From 588,398 Procedures in the National Cardiovascular Data.
Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Presidential address: quality of cardiovascular.
  Aldosterone Targeted NeuroHormonal CombinEd with Natriuresis TherApy – Heart Failure Trial ATHENA-HF Trial Javed Butler, M.D., M.P.H, M.B.A. On behalf.
Prognostic Value of B-Type Natriuretic Peptides in Patients With Stable Coronary Artery Disease: The PEACE Trial Torbjørn Omland, MD, PHD, MPH, Marc S.
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure  Clyde W. Yancy, MD, MSc, MACC, FAHA, FHFSA, Mariell.
The Association of Five-Year Changes in the Levels of N-Terminal Fragment of the Prohormone Brain-Type Natriuretic Peptide (NT-proBNP) with Subsequent.
Revascularization in Patients With Left Ventricular Dysfunction:
NT–probrain natriuretic peptide predicts complexity and severity of the coronary lesions in patients with non–ST-elevation acute coronary syndromes  José.
Copyright © 2007 American Medical Association. All rights reserved.
BNP in Heart Failure Azam Hadi MD 9/17/2018.
Stephen W. Waldo et al. JACC 2008;51:
Cardiovacular Research Technologies
Cardiac Biomarkers.
Biomarkers in Heart Failure
Discharge instructions
Median NT-proBNP levels (pg/mL) by GFR and 60-day survival
Figure 4 BMI and mortality in patients with heart failure
Clyde W. Yancy et al. JACC 2017;70:
Baseline and Serial Brain Natriuretic Peptide Level Predicts 5-Year Overall Survival in Patients With Pulmonary Arterial Hypertension: Data From the REVEAL.
Cardiac Biomarkers: Key Takeaways for Use in Heart Failure and Acute Coronary Syndrome.
INOVATE-HF Trial design: Patients with heart failure (HF) were randomized to device implant for vagus nerve stimulation (n = 436) versus optimal medical.
Biomarker-Guided HF Therapy: Is It Cost-Effective?
Expert Insights on Complex Clinical Cases of Edema
The Heart Failure Team Heart Failure Care Map First 24 hours.
G. Michael Felker et al. JCHF 2014;2:
Brian P. Shapiro, MD, Horng H. Chen, MD, John C
Editorial Heart Failure Clinics
Sexual Activity and Chronic Heart Failure
Overcoming Clinical Inertia
Division of Cardiovascular Diseases No relevant author disclosures
Diagnostic and Prognostic Utility of Procalcitonin in Patients Presenting to the Emergency Department with Dyspnea  George A. Alba, MD, Quynh A. Truong,
Baseline Characteristics of Cardiovascular Risk Factors and Selected Dietary Variables in a Cohort of 22,881 Men and 35,091 Women to Quintile of Fish Intakes.
Baseline Characteristics by Baseline N-BNP Level
Risk assessment and treat-to-target approach for pulmonary arterial hypertension. Risk assessment and treat-to-target approach for pulmonary arterial hypertension.
Michael H. Chiu, MD, Msc, Nakul C. Sharma, MD, MPH  CJC Open 
The possible off-target effect of increased heart failure hospitalizations from saxagliptin in the SAVOR trial. The possible off-target effect of increased.
Figure 1 Novel markers of increased stroke risk in AF
Analysis of receiver operating characteristic of three models (model 1: cardiac troponin T (cTnT), N-terminal pro brain natriuretic peptide (NT-proBNP),
Mayo Clinic Proceedings
Presentation transcript:

Admission B-Type Natriuretic Peptide Levels and In-Hospital Mortality in Acute Decompensated Heart Failure Fonarow GC et al. J Am Coll Cardiol 2007; 49(19): Gregg C. Fonarow MD, FACC, William F. Peacock MD, Christopher O. Phillips MD, MPH, Michael M. Givertz MD, FACC, Margarita Lopatin MS and ADHERE Scientific Advisory Committee and Investigators

Admission BNP and In-Hospital Mortality in ADHF Levels of BNP and NT-proBNP have been shown to be elevated in patients with left ventricular (LV) dysfunction and correlate with the New York Heart Association functional classLevels of BNP and NT-proBNP have been shown to be elevated in patients with left ventricular (LV) dysfunction and correlate with the New York Heart Association functional class Clinical investigations of natriuretic peptides have focused on the diagnostic usefulness for heart failure (HF) and LV dysfunction and their prognostic usefulness in chronic HF, acute coronary syndromes, stable coronary artery disease, other medical conditions, and community cohortsClinical investigations of natriuretic peptides have focused on the diagnostic usefulness for heart failure (HF) and LV dysfunction and their prognostic usefulness in chronic HF, acute coronary syndromes, stable coronary artery disease, other medical conditions, and community cohorts Whether plasma levels of BNP are predictive of in-hospital mortality risk in patients hospitalized with acute decompensated HF has not been well studiedWhether plasma levels of BNP are predictive of in-hospital mortality risk in patients hospitalized with acute decompensated HF has not been well studied Fonarow GC et al. J Am Coll Cardiol 2007; 49(19):

The ADHERE (Acute Decompensated Heart Failure National Registry) Registry Multicenter Observational Open label Electronic web-based Registry of the management of patients treated in hospitals for acutely decompensated heart failure in the US The ADHERE Registry Fonarow GC et al. J Am Coll Cardiol 2007; 49(19):

Initial BNP Levels in ADHERE Time Period: Q – Q out of 229 ADHERE hospitals (176 BNP only, 15 BNP and pro-BNP, 14 pro-BNP only, 24 none) First BNP result, within 24 hours of admission Results as documented in medical record 48,629 (63%) out of 77,467 pt episodes had BNP assessment Analysis by BNP quartiles, continuous, and log transformed BNP Fonarow GC et al. J Am Coll Cardiol 2007; 49(19):

Admission BNP and In-Hospital Mortality in ADHF Distribution of BNP Values (pg/mL) 48,629 (63%) out of 77,467 pt episodes had BNP assessment at initial evaluation. Only 3.3% of patients in ADHERE with initial BNP < 100 pg/mL Fonarow GC et al. J Am Coll Cardiol 2007; 49(19):

Admission BNP and In-Hospital Mortality in ADHF BNP QuartilesBNP Quartiles –Quartile I: < 430 pg/mL –Quartile II: 430 – 839 pg/mL –Quartile III: 840 – 1729 pg/mL –Quartile IV: > 1730 pg/mL Fonarow GC et al. J Am Coll Cardiol 2007; 49(19):

Patient Characteristics by Quartiles of BNP Levels in the ADHERE Registry Q1 (<430)N=12,161 Q2 ( )N=12,146 Q3 ( )N=12,156 Q4 (>1730)N=12,166 P Value Age P< Male (%) P< White (%) P< Hx HF P< CAD P< Prior MI P< HTN P= Diabetes P< AFib P< CRI Hx P< Dialysis P< Fonarow GC et al. J Am Coll Cardiol 2007; 49(19):

Patient Characteristics by Quartiles of BNP Levels in the ADHERE Registry Q1 (<430) Q2 ( ) Q3 ( ) Q4 (>1730) P Value SOB rest P< Rales P< SBP P< HR P= Sodium P< BUN P< Cr P< CXR cong P< LVEF P< % LVEF < P< Fonarow GC et al. J Am Coll Cardiol 2007; 49(19):

Patient IV Treatments by Quartiles of BNP Levels in the ADHERE Registry Q1 (<430) Q2 ( ) Q3 ( ) Q4 (>1730) P Value Diuretic P< Time to Rx7.0 hrs6.9 hrs6.6 hrs6.9 hrsP= Vasoactive P< Inotrope P< Vasodilator P< NTG P< Nesiritide P< Fonarow GC et al. J Am Coll Cardiol 2007; 49(19):

Q1<430N=12,161Q N=12,146Q N=12,156Q4 >1730 N=12,166 P Value Oral Medications ACE Inhibitors (%) <.0001 ARBs (%) <.0001 Beta Blockers (%) <.0001 Calcium Blockers (%) <.0001 Digoxin (%) <.0001 Diuretics (%) <.0001 Peripheral Vasodilators (%) <.0001 Warfarin (%) <.0001 Admission BNP and In-Hospital Mortality in ADHF In-hospital Medications Fonarow GC et al. J Am Coll Cardiol 2007; 49(19):

In-Hospital Mortality Risk by Initial BNP Levels in the ADHERE Registry P< Fonarow GC et al. J Am Coll Cardiol 2007; 49(19):

In-Hospital Mortality Risk by Initial BNP Levels in the ADHERE Registry BNP Quartiles CategoryII vs. IIII vs. IIV vs. I Total N12,146 vs. 12,16112,156 vs. 12,16112,166 vs. 12,161 Unadjusted ( ) p< ( ) p< ( ) p<.0001 Adjusted ( ) p= ( ) p< ( ) p<.0001 Adjusted ( ) p= ( ) p< ( ) p<.0001 Adjusted ( ) p= ( ) p< ( ) p<.0001 Adjusted ( ) p= ( ) p< ( ) p< Area under the ROC curve (AUC)= Age, gender. AUC= Age, gender, BUN, systolic BP, creatinine. AUC= Age, gender, BUN, systolic BP, creatinine, LVEF<.40 or Mod./Sev. AUC= Age, gender, BUN, systolic BP, creatinine, sodium, pulse, dyspnea at rest. AUC=0.77. Odds Ratios (95% CI), p-value

In-Hospital Mortality Risk by Initial BNP Levels Reduced vs. Preserved Systolic Function HF P< LVEF < 0.40 LVEF > 0.40 Fonarow GC et al. J Am Coll Cardiol 2007; 49(19):

In-Hospital Mortality Risk by Initial BNP Levels in the ADHERE Registry

ADMISSION TO THE ICU STRATIFIED BY BNP QUARTILE % P<.0001 Fonarow GC et al. J Am Coll Cardiol 2007; 49(19):

TOTAL HOSPITAL LENGTH OF STAY STRATIFIED BY BNP QUARTILE Median Days P<.0001 Fonarow GC et al. J Am Coll Cardiol 2007; 49(19):

Patient Outcomes by Quartiles of BNP Levels in the ADHERE Registry Q1 (<430) Q2 ( ) Q3 ( ) Q4 (>1730) P Value Ventilation P= CPR P< Ultrafiltrat P< LOS (days) P< ICU admit % P< ASx at DC P< Fonarow GC et al. J Am Coll Cardiol 2007; 49(19):

Admission BNP and In-Hospital Mortality in ADHF Study Limitations Data collected from chart review which is dependent on the accuracy and completeness of documentation and abstractionData collected from chart review which is dependent on the accuracy and completeness of documentation and abstraction This “real world” study used results of various commercially available BNP assays vs. results from single central core laboratoryThis “real world” study used results of various commercially available BNP assays vs. results from single central core laboratory Individual hospitalization episodes vs. individual unique patientsIndividual hospitalization episodes vs. individual unique patients –Each hospitalization represents unique opportunity to either survive or not survive. Fonarow GC et al. J Am Coll Cardiol 2007; 49(19):

Admission BNP and In-Hospital Mortality in ADHF Elevated admission BNP is a significant predictor of in- hospital mortality in ADHF, independent of other risk factorsElevated admission BNP is a significant predictor of in- hospital mortality in ADHF, independent of other risk factors BNP is predictive of mortality in both patients with reduced and those with preserved LVEFBNP is predictive of mortality in both patients with reduced and those with preserved LVEF Further research necessary to determine whether pts with higher admission BNP would benefit from more intensive monitoring and/or aggressive treatment strategiesFurther research necessary to determine whether pts with higher admission BNP would benefit from more intensive monitoring and/or aggressive treatment strategies Fonarow GC et al. J Am Coll Cardiol 2007; 49(19):

Acknowledgments Acknowledgments The ADHERE Scientific Advisory Committee and Investigators